Cabergoline, a long-acting dopamine D2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naive primates

Brain Research

Volumn 735, Issue 2, 1996, Pages 298-306

  Grondin, R ^a   Goulet, M ^b   Di Paolo, T ^b   Bedard P J ^a  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Cabergoline; Dopamine D; Dyskinesia; GABA; MPTP; Parkinson's disease; Receptor

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 4 AMINOBUTYRIC ACID A RECEPTOR; CABERGOLINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DYSKINESIA; FEMALE; LOCOMOTION; MONKEY; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PUTAMEN; RECEPTOR BINDING; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030574099     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-8993(96)00597-5     Document Type: Article

References (54)

1. [1] Alexander, G.M., Brainard, D.L., Gordon, S.W., Hichens, M., Grothusen, J.R. and Schwartzman, R.J., Dopamine receptor change in untreated and (+)-PHNO-treated MPTP parkinsonian primates, Brain Res., 547 (1991) 181-189.
2. [2] Alhskog, J.E., Muenter, M.D., Maraganore, D.M., Matsumoto, J.Y., Lieberman, A., Wright, K.F. and Wheeler, K., Fluctuating Parkinson's disease: treatment with the long-acting dopamine agonist cabergoline, Arch. Neurol., 51 (1994) 1236-1241.
3. 3H]spiperone binding, Brain Res., 379 (1986) 294-299.
4. [4] Blanchet, P.J., Gomez-Mancilla, B., Di Paolo, T. and Bédard, P.J., Is striatal dopaminergic receptor imbalance responsible for levodopa-induced dyskinesias? Fund. Clin. Pharmacol., 9 (1995) 434-442.
5. [5] Blanchet, P.J., Calon, F., Martel, J.C., Bédard, P.J., Di Paolo, T., Walters, R.R. and Piercey, M.F., Continuous administration decrease and pulsatile administration increase behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys, J. Pharmacol. Exp. Ther., 272 (1995) 854-859.
6. [6] Boyce, S., Rupniak, N.M.J., Steventon, M.J. and Iversen, S.D., Nigrostriatal damaged is required for the induction of dyskinesias by L-DOPA in squirrel monkeys, Clin. Neuropharmacol., 13 (1990) 448-458.
7. A receptors in the striatopallidal complex, Brain Res., 680 (1995) 43-52.
8. [8] Cedarbaum, J.M., Silvestri, M. and Kutt, H., Sustained enteral administration of levodopa increase and interrupted infusion decreases levodopa dose requirements, Neurology, 40 (1990) 995-997.
9. [9] Cedarbaum, J.M., Clarck, M., Toy, L.H. and Green-Parsons, A., Sustained-release (+)-PHNO [MK-458(HPMC)] in the treatment of Parkinson's disease: evidence for tolerance to a selective D2-receptor agonist administered as a long-acting formulation, Movement Disord., 5 (1990) 298-303.
10. [10] Crossman, A.R., A hypothesis on the pathophysiological mechanism that underlie levodopa-or dopamine agonist-induced dyskinesia in parkinson's disease: implications for future strategies in treatment, Movement Disord., 5 (1990) 100-108.
11. [11] Di Paolo, T., Bédard, P.J., Daigle, M. and Boucher, R., Long-term effects of MPTP on central and peripheral catecholamine and indolamine concentration in monkeys, Brain Res., 379 (1986) 286-293.
12. [12] Doucet, J.-P., Nakabeppu, Y., Bédard, P.J., Hope, B.T., Nestler, E.J., Jasmin, B.J., Chen, J.-S., Iadarola, M.J., St-Jean, M., Wigle, N., Blanchet, P., Grondin, R. and Robertson, G.S., Chronic alterations in dopaminergic neuro-transmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum, Eur. J. Neurosci., 8 (1996) 365-381.
13. [13] Engber, T.M., Susel, Z., Kuo, S., Gerfen, C.R. and Chase, T.N., Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats, Brain Res., 552 (1991) 113-118.
14. 2 dopamine agonists in MPTP monkeys, Eur. J. Pharmacol. 150 (1988) 59-66.
15. [15] Fariello, R.G., Carfagna, N., Bunoamici, M. and Dubini, A., Cabergoline: a long-acting D-2 agonist with antiparkinsonian properties. Preclinical studies, Ann. Neurol., 30 (1991) 258.
16. [16] Frankel, J.P., Lees, A.J., Kempster, P.A. and Stern, G.M., Subcutaneous apomorphine in the treatment of Parkinson's disease, J. Neurol. Neurosurg. Psychol., 53 (1990) 96-101.
17. 2 receptor agonist, Eur. J. Pharmacol., 178 (1990) 115-120.
18. [18] Gancher, S.T., Nutt, J.G. and Woodward, W.R., Apomorphine infusional therapy in Parkinson's disease: clinical utility and lack of tolerance, Movement Disord., 10 (1995) 37-43.
19. 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons, Science, 250 (1990) 1429-1432.
20. 3H]flunitrazepam, Neuroscience, 57 (1993) 673-678.
21. 1 receptor binding in the striatum following a selective lesion of striatopallidal neurons, Brain Res., 590 (1992) 305-310.
22. [22] Herrero, M.-T., Augood, S.J., Hirsch, E.C., Javoy-Agid, F., Luquin, M.R., Agid, Y., Obeso, J.A. and Emson, P.C., Effect of L-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum, Neuroscience, 68 (1995) 1189-1198.
23. [23] Hughes, A.J., Bishop, S., Kleedorfer, B., Turjanski, N., Fernandez, W., Lees, A.J. and Stern G.M., Subcutaneous apomorphine in Parkinson's disease to chronic administration for up to five years, Movement Disord., 8 (1993) 165-170.
24. [24] Hutton, J.T., Morris, J.L. and Brewer, M., Controlled study of the antiparkinsonian activity and tolerability of cabergoline, Neurology, 43 (1993) 613-616.
25. [25] Inzelberg, R., Nisipeanu, P., Rabey, M.J. and Korczyn, A.D., Long-term tolerability and efficacy of cabergoline, a new long-acting dopamine agonist, in Parkinson's disease, Movement Disord., 10 (1995) 604-607.
26. [26] Jolkkonen, J., Jenner, P. and Marsden, D.C., L-DOPA reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP, Mol. Brain Res., 32 (1995) 297-307.
27. [27] Kebabian, J.W. and Calne, D.B., Multiple receptors for dopamine, Nature, 277 (1979) 93-96.
28. [28] Kurth, M.C., Tetrud, J.W., Tanner, C.M., Irwin, I., Stebbins, G.T., Goetz, C.G. and Langston, J.W., Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off fluctuations, Neurology, 43 (1993) 1698-1703.
29. [29] Lahti, R.A., Roberts, R.C. and Tamminga, C.A., D2-Family receptor distribution in human postmortem tissue: an autoradiographic study, Neuro Report, 6 (1995) 2505-2512.
30. [30] Lees, A.J. and Stern, G.M., Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease, J. Neurol. Neurosurg. Psychol., 44 (1981) 1020-1023.
31. [31] Le Moine, C., Normand, E. and Bloch, B., Phenotypical characterization of the rat striatal neurons expressing the D1 dopamine receptor gene, Proc. Natl. Acad. Sci. USA, 88 (1991) 4205-4209.
32. [32] Lera, G., Vaamonde, J., Rodriguez, M. and Obeso, J.A., Cabergoline in Parkinson's disease: long-term follow-up, Neurology, 43 (1993) 2587-2590.
33. [33] Lieberman, A., Imke, S., Wheeler, K., Alhskog, J.E., Matsumoto, J.Y., Maragnanore, D.M., Wright, K.F. and Schoenfelder, J., Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa, Neurology, 43 (1993) 1981-984.
34. [34] Mouradian, M.M., Heuser, I.J.E., Barontil, F. and Chase, T.N., Modifications of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease, Ann. Neurol., 27 (1990) 18-23.
35. [35] Mouradian, M.M., Juncos, J.L., Fabrini, G. and Chase, T.N., Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies, Ann. Neurol., 22 (1987) 475-479.
36. [36] Mouradian, M.M., Heuser, I.J.E., Barontil, F., Fabrini, G., Juncos, J.L. and Chase, T.N., Pathogenesis of dyskinesias in Parkinson's disease, Ann. Neurol., 25 (1989) 523-526.
37. 3H]flunitrazepam in the rat brain under hypoxia, J. Neurochem., 51 (1998) 1111-1117.
38. [38] Nutt, J.G., Levodopa-induced dyskinesia: review, observations, and speculations, Neurology, 40 (1990) 340-345.
39. [39] Obeso, J.A., Martinez-Lage, J.M., Luquin, M.R. and Bolio, N., Intravenous lisuride infusion for Parkinson's disease, Lancet, 2 (1982) 252.
40. [40] Pontiroli, A.E., Viberti, G.C., Mangili, R., Cammelli, L. and Dubini, A., Selective and extremely long inhibition of prolactin release in man by 1-ethyl-3-(3′-dimethylaminopropyl)-3-(6′-allylergolin-8′-β-carbonyl)-urea diphosphate (FCE 21336), Br. J. Clin. Pharmacol., 23 (1987) 433-438.
41. [41] Post, R., Intermittent versus continuous stimulation: effect of time interval on the development of sensitization or tolerance, Life Sci., 26 (1980) 1275-1282.
42. [42] Quinn, N., Parkes, D. and Marsden, D., Complicated response fluctuations in Parkinson's disease: response to intravenous infusion of levodopa, Lancet, 2 (1982) 412-415.
43. [43] Quinn, N., Parkes, D. and Marsden, D., Control of on/off phenomenon by continuous intravenous infusion of levodopa, Neurology, 34 (1984) 1131-1136.
44. [44] Sage, J.I., Trooskin, S., Sonsalla, P.K., Heikkila, R. and Duvoisin, R.C., Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonism, Ann. Neurol., 24 (1988) 87-89.
45. [45] Schneider, J.S., Levodopa-induced dyskinesia in parkinsonian monkeys: relationship to extent of nigrostriatal damage, Pharmacol. Biochem. Behav., 34 (1989) 193-196.
46. [46] Schuh, L.A. and Bennett Jr., J.P., Suppression of dyskinesias in advanced Parkinson's disease. I. Continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease, Neurology, 43 (1993) 1545-1550.
47. [47] Sibley, D. and Monsma Jr., F.J., Molecular biology of dopamine receptors, Trends Pharmacol. Sci., 13 (1992) 61-68.
48. [48] Stibe, C.M.H., Kempster, P.A., Lees, A.J. and Stern, G.M., Subcutaneous apomorphine in parkinsonian on-off oscillations, Lancet, 1 (1988) 403-406.
49. 3H]N-n-propylnorapomorphine, Eur. J. Pharmacol., 187 (1990) 399-408.
50. [50] Surmeier, J.D., Reiner, A., Levine, M.S. and Ariano, M., Are neostriatal dopamine receptors co-localized?, Trends Neurosci., 16 (1993) 229-305.
51. [51] Svensson, K., Carlsson, A., Huff, R., Kling-Petersen, T. and Waters, N., Behavioral and neurochemical data suggest functional differences between dopamine D2 and D3 receptors, Eur. J. Pharmacol., 263 (1994) 235-243.
52. [52] Vaamonde, J., Luquin, M.R. and Obeso, J.A., Subcutaneous lisuride infusion in Parkinson's disease: response to chronic administration in 34 patients, Brain, 114 (1991) 601-614.
53. [53] Winkler, J.D. and Weiss, B., Effect of continuous exposure to selective D-1 and D-2 dopaminergic agonists on rotational behavior in supersensitive mice, J. Pharmacol. Exp. Ther., 249 (1989) 507-516.
54. [54] Yung, K.K.L., Bolam, J.P., Smith, A.D., Hersch, S.M., Ciliax, B.J. and Levey, A.I., Immunocytochemical localization of D1 and D2 dopamine receptors in the basal ganglia of the rat: light and electron microscopy, Neuroscience, 65 (1995) 709-730.